<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36293362</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>20</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Molecular Dissection of TDP-43 as a Leading Cause of ALS/FTLD.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">12508</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms232012508</ELocationID><Abstract><AbstractText>TAR DNA binding protein 43 (TDP-43) is a DNA/RNA binding protein involved in pivotal cellular functions, especially in RNA metabolism. Hyperphosphorylated and ubiquitinated TDP-43-positive neuronal cytoplasmic inclusions are identified in the brain and spinal cord in most cases of amyotrophic lateral sclerosis (ALS) and a substantial proportion of frontotemporal lobar degeneration (FTLD) cases. TDP-43 dysfunctions and cytoplasmic aggregation seem to be the central pathogenicity in ALS and FTLD. Therefore, unraveling both the physiological and pathological mechanisms of TDP-43 may enable the exploration of novel therapeutic strategies. This review highlights the current understanding of TDP-43 biology and pathology, describing the cellular processes involved in the pathogeneses of ALS and FTLD, such as post-translational modifications, RNA metabolism, liquid-liquid phase separation, proteolysis, and the potential prion-like propagation propensity of the TDP-43 inclusions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tamaki</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urushitani</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2773-9836</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Shiga University of Medical Science, Otsu 520-2192, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JP20K22682</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="Y">Prions</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">FTLD</Keyword><Keyword MajorTopicYN="N">RNA metabolism</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">aggregation</Keyword><Keyword MajorTopicYN="N">neurodegenerative diseases</Keyword><Keyword MajorTopicYN="N">phase separation</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>27</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36293362</ArticleId><ArticleId IdType="pmc">PMC9604209</ArticleId><ArticleId IdType="doi">10.3390/ijms232012508</ArticleId><ArticleId IdType="pii">ijms232012508</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS genetics, mechanisms, and therapeutics: Where are we now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang J., Spina S., Miller B.L. Frontotemporal dementia. Lancet. 2015;386:1672&#x2013;1682. doi: 10.1016/S0140-6736(15)00461-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)00461-4</ArticleId><ArticleId IdType="pmc">PMC5970949</ArticleId><ArticleId IdType="pubmed">26595641</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell J.R., Halliday G.M., Kril J.J., Ittner L.M., G&#xf6;tz J., Kiernan M.C., Hodges J.R. The frontotemporal dementia-motor neuron disease continuum. Lancet. 2016;388:919&#x2013;931. doi: 10.1016/S0140-6736(16)00737-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)00737-6</ArticleId><ArticleId IdType="pubmed">26987909</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringholz G.M., Appel S.H., Bradshaw M., Cooke N.A., Mosnik D.M., Schulz P.E. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005;65:586&#x2013;590. doi: 10.1212/01.wnl.0000172911.39167.b6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000172911.39167.b6</ArticleId><ArticleId IdType="pubmed">16116120</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S.C., Polymenidou M., Cleveland D.W. Converging mechanisms in ALS and FTD: Disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B., Bonvicini C., Alberici A., Buratti E., Agosti C., Archetti S., Papetti A., Stuani C., Di Luca M., Gennarelli M., et al. Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease. Hum. Mutat. 2009;30:E974&#x2013;E983. doi: 10.1002/humu.21100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.21100</ArticleId><ArticleId IdType="pubmed">19655382</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E., Valdmanis P.N., Dion P., Spiegelman D., McConkey B.J., Vande Velde C., Bouchard J.P., Lacomblez L., Pochigaeva K., Salachas F., et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008;40:572&#x2013;574. doi: 10.1038/ng.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.132</ArticleId><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs G.G., Murrell J.R., Horvath S., Haraszti L., Majtenyi K., Molnar M.J., Budka H., Ghetti B., Spina S. TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. Mov. Disord. 2009;24:1843&#x2013;1847. doi: 10.1002/mds.22697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22697</ArticleId><ArticleId IdType="pubmed">19609911</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L., Buratti E., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J., Wang L., Huntley M.L., Perry G., Wang X. Pathomechanisms of TDP-43 in neurodegeneration. J. Neurochem. 2018;146:7&#x2013;20. doi: 10.1111/jnc.14327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14327</ArticleId><ArticleId IdType="pmc">PMC6110993</ArticleId><ArticleId IdType="pubmed">29486049</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson P.T., Dickson D.W., Trojanowski J.Q., Jack C.R., Boyle P.A., Arfanakis K., Rademakers R., Alafuzoff I., Attems J., Brayne C., et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): Consensus working group report. Brain. 2019;142:1503&#x2013;1527. doi: 10.1093/brain/awz099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz099</ArticleId><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Wider C., Dickson D.W., Stoessl A.J., Tsuboi Y., Chapon F., Gutmann L., Lechevalier B., Calne D.B., Personett D.A., Hulihan M., et al. Pallidonigral TDP-43 pathology in Perry syndrome. Park. Relat. Disord. 2009;15:281&#x2013;286. doi: 10.1016/j.parkreldis.2008.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2008.07.005</ArticleId><ArticleId IdType="pmc">PMC2693935</ArticleId><ArticleId IdType="pubmed">18723384</ArticleId></ArticleIdList></Reference><Reference><Citation>De Boer E.M.J., Orie V.K., Williams T., Baker M.R., De Oliveira H.M., Polvikoski T., Silsby M., Menon P., Van den Bos M., Halliday G.M., et al. TDP-43 proteinopathies: A new wave of neurodegenerative diseases. J. Neurol. Neurosurg. Psychiatry. 2020;92:86&#x2013;95. doi: 10.1136/jnnp-2020-322983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322983</ArticleId><ArticleId IdType="pmc">PMC7803890</ArticleId><ArticleId IdType="pubmed">33177049</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M., Lagier-Tourenne C., Hutt K.R., Huelga S.C., Moran J., Liang T.Y., Ling S.C., Sun E., Wancewicz E., Mazur C., et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 2011;14:459&#x2013;468. doi: 10.1038/nn.2779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2779</ArticleId><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey J.R., Curk T., Rogelj B., Briese M., Cereda M., Kayikci M., K&#xf6;nig J., Hortob&#xe1;gyi T., Nishimura A.L., Zupunski V., et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat. Neurosci. 2011;14:452&#x2013;458. doi: 10.1038/nn.2778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2778</ArticleId><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Riku Y., Seilhean D., Duyckaerts C., Boluda S., Iguchi Y., Ishigaki S., Iwasaki K., Yoshida M., Sobue G., Katsuno M. Pathway from TDP-43-related pathology to neuronal dysfunction in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Int. J. Mol. Sci. 2021;22:3843. doi: 10.3390/ijms22083843.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22083843</ArticleId><ArticleId IdType="pmc">PMC8068029</ArticleId><ArticleId IdType="pubmed">33917673</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday G., Bigio E.H., Cairns N.J., Neumann M., Mackenzie I.R., Mann D.M. Mechanisms of disease in frontotemporal lobar degeneration: Gain of function versus loss of function effects. Acta Neuropathol. 2012;124:373&#x2013;382. doi: 10.1007/s00401-012-1030-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1030-4</ArticleId><ArticleId IdType="pmc">PMC3445027</ArticleId><ArticleId IdType="pubmed">22878865</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G., Gautier O., Tassoni-Tsuchida E., Ma X.R., Gitler A.D. ALS genetics: Gains, losses, and implications for future therapies. Neuron. 2020;108:822&#x2013;842. doi: 10.1016/j.neuron.2020.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.022</ArticleId><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen T.J., Lee V.M., Trojanowski J.Q. TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol. Med. 2011;17:659&#x2013;667. doi: 10.1016/j.molmed.2011.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2011.06.004</ArticleId><ArticleId IdType="pmc">PMC3202652</ArticleId><ArticleId IdType="pubmed">21783422</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L.L., Zhao J., Yin X.F., He W.T., Yang H., Che M.X., Hu H.Y. Two mutations G335D and Q343R within the amyloidogenic core region of TDP-43 influence its aggregation and inclusion formation. Sci. Rep. 2016;6:23928. doi: 10.1038/srep23928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep23928</ArticleId><ArticleId IdType="pmc">PMC4814915</ArticleId><ArticleId IdType="pubmed">27030292</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo P.H., Chiang C.H., Wang Y.T., Doudeva L.G., Yuan H.S. The crystal structure of TDP-43 RRM1-DNA complex reveals the specific recognition for UG- and TG-rich nucleic acids. Nucleic Acids Res. 2014;42:4712&#x2013;4722. doi: 10.1093/nar/gkt1407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1407</ArticleId><ArticleId IdType="pmc">PMC3985631</ArticleId><ArticleId IdType="pubmed">24464995</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukavsky P.J., Daujotyte D., Tollervey J.R., Ule J., Stuani C., Buratti E., Baralle F.E., Damberger F.F., Allain F.H. Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. Nat. Struct. Mol. Biol. 2013;20:1443&#x2013;1449. doi: 10.1038/nsmb.2698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2698</ArticleId><ArticleId IdType="pubmed">24240615</ArticleId></ArticleIdList></Reference><Reference><Citation>Mompe&#xe1;n M., Romano V., Pantoja-Uceda D., Stuani C., Baralle F.E., Buratti E., Laurents D.V. The TDP-43 N-terminal domain structure at high resolution. FEBS J. 2016;283:1242&#x2013;1260.</Citation><ArticleIdList><ArticleId IdType="pubmed">26756435</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin H., Lim L.Z., Wei Y., Song J. TDP-43 N terminus encodes a novel ubiquitin-like fold and its unfolded form in equilibrium that can be shifted by binding to ssDNA. Proc. Natl. Acad. Sci. USA. 2014;111:18619&#x2013;18624. doi: 10.1073/pnas.1413994112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1413994112</ArticleId><ArticleId IdType="pmc">PMC4284588</ArticleId><ArticleId IdType="pubmed">25503365</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiina Y., Arima K., Tabunoki H., Satoh J. TDP-43 dimerizes in human cells in culture. Cell. Mol. Neurobiol. 2010;30:641&#x2013;652. doi: 10.1007/s10571-009-9489-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-009-9489-9</ArticleId><ArticleId IdType="pubmed">20043239</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.J., Caulfield T., Xu Y.F., Gendron T.F., Hubbard J., Stetler C., Sasaguri H., Whitelaw E.C., Cai S., Lee W.C., et al. The dual functions of the extreme N-terminus of TDP-43 in regulating its biological activity and inclusion formation. Hum. Mol. Genet. 2013;22:3112&#x2013;3122. doi: 10.1093/hmg/ddt166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt166</ArticleId><ArticleId IdType="pmc">PMC3699067</ArticleId><ArticleId IdType="pubmed">23575225</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.K., Wu T.H., Wu C.Y., Chiang M.H., Toh E.K., Hsu Y.C., Lin K.F., Liao Y.H., Huang T.H., Huang J.J. The N-terminus of TDP-43 promotes its oligomerization and enhances DNA binding affinity. Biochem. Biophys. Res. Commun. 2012;425:219&#x2013;224. doi: 10.1016/j.bbrc.2012.07.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2012.07.071</ArticleId><ArticleId IdType="pubmed">22835933</ArticleId></ArticleIdList></Reference><Reference><Citation>Afroz T., Hock E.M., Ernst P., Foglieni C., Jambeau M., Gilhespy L.A.B., Laferriere F., Maniecka Z., Pl&#xfc;ckthun A., Mittl P., et al. Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. Nat. Commun. 2017;8:45. doi: 10.1038/s41467-017-00062-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00062-0</ArticleId><ArticleId IdType="pmc">PMC5491494</ArticleId><ArticleId IdType="pubmed">28663553</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A., Conicella A.E., Schmidt H.B., Martin E.W., Rhoads S.N., Reeb A.N., Nourse A., Ramirez Montero D., Ryan V.H., Rohatgi R., et al. A single N-terminal phosphomimic disrupts TDP-43 polymerization, phase separation, and RNA splicing. EMBO J. 2018;37:E97452. doi: 10.15252/embj.201797452.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201797452</ArticleId><ArticleId IdType="pmc">PMC5830921</ArticleId><ArticleId IdType="pubmed">29438978</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo P.H., Doudeva L.G., Wang Y.T., Shen C.K., Yuan H.S. Structural insights into TDP-43 in nucleic-acid binding and domain interactions. Nucleic Acids Res. 2009;37:1799&#x2013;1808. doi: 10.1093/nar/gkp013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkp013</ArticleId><ArticleId IdType="pmc">PMC2665213</ArticleId><ArticleId IdType="pubmed">19174564</ArticleId></ArticleIdList></Reference><Reference><Citation>Shodai A., Ido A., Fujiwara N., Ayaki T., Morimura T., Oono M., Uchida T., Takahashi R., Ito H., Urushitani M. Conserved acidic amino acid residues in a second RNA recognition motif regulate assembly and function of TDP-43. PLoS ONE. 2012;7:E52776. doi: 10.1371/journal.pone.0052776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052776</ArticleId><ArticleId IdType="pmc">PMC3530536</ArticleId><ArticleId IdType="pubmed">23300771</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaki Y., Shodai A., Morimura T., Hikiami R., Minamiyama S., Ayaki T., Tooyama I., Furukawa Y., Takahashi R., Urushitani M. Elimination of TDP-43 inclusions linked to amyotrophic lateral sclerosis by a misfolding-specific intrabody with dual proteolytic signals. Sci. Rep. 2018;8:6030. doi: 10.1038/s41598-018-24463-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-24463-3</ArticleId><ArticleId IdType="pmc">PMC5902603</ArticleId><ArticleId IdType="pubmed">29662239</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunde B.M., Moore C., Varani G. RNA-binding proteins: Modular design for efficient function. Nat. Rev. Mol. Cell Biol. 2007;8:479&#x2013;490. doi: 10.1038/nrm2178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2178</ArticleId><ArticleId IdType="pmc">PMC5507177</ArticleId><ArticleId IdType="pubmed">17473849</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling J.P., Pletnikova O., Troncoso J.C., Wong P.C. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349:650&#x2013;655. doi: 10.1126/science.aab0983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab0983</ArticleId><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyama A., Sugai A., Kato T., Ishihara T., Shiga A., Toyoshima Y., Koyama M., Konno T., Hirokawa S., Yokoseki A., et al. Increased cytoplasmic TARDBP mRNA in affected spinal motor neurons in ALS caused by abnormal autoregulation of TDP-43. Nucleic Acids Res. 2016;44:5820&#x2013;5836. doi: 10.1093/nar/gkw499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw499</ArticleId><ArticleId IdType="pmc">PMC4937342</ArticleId><ArticleId IdType="pubmed">27257061</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami N.H., Smith R.B., Carrasco M.A., Williams L.A., Winborn C.S., Han S.S.W., Kiskinis E., Winborn B., Freibaum B.D., Kanagaraj A., et al. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron. 2014;81:536&#x2013;543. doi: 10.1016/j.neuron.2013.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.12.018</ArticleId><ArticleId IdType="pmc">PMC3939050</ArticleId><ArticleId IdType="pubmed">24507191</ArticleId></ArticleIdList></Reference><Reference><Citation>Shodai A., Morimura T., Ido A., Uchida T., Ayaki T., Takahashi R., Kitazawa S., Suzuki S., Shirouzu M., Kigawa T., et al. Aberrant assembly of RNA recognition motif 1 links to pathogenic conversion of TAR DNA-binding protein of 43 kDa (TDP-43) J. Biol. Chem. 2013;288:14886&#x2013;14905. doi: 10.1074/jbc.M113.451849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.451849</ArticleId><ArticleId IdType="pmc">PMC3663511</ArticleId><ArticleId IdType="pubmed">23558684</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabdano S.O., Izmailov S.A., Luzik D.A., Groves A., Podkorytov I.S., Skrynnikov N.R. Onset of disorder and protein aggregation due to oxidation-induced intermolecular disulfide bonds: Case study of RRM2 domain from TDP-43. Sci. Rep. 2017;7:11161. doi: 10.1038/s41598-017-10574-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-10574-w</ArticleId><ArticleId IdType="pmc">PMC5593996</ArticleId><ArticleId IdType="pubmed">28894122</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A., Bharathi V., Sivalingam V., Girdhar A., Patel B.K. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front. Mol. Neurosci. 2019;12:25. doi: 10.3389/fnmol.2019.00025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00025</ArticleId><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella A.E., Zerze G.H., Mittal J., Fawzi N.L. ALS Mutations disrupt phase separation mediated by &#x3b1;-helical structure in the TDP-43 low-complexity C-terminal domain. Structure. 2016;24:1537&#x2013;1549. doi: 10.1016/j.str.2016.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2016.07.007</ArticleId><ArticleId IdType="pmc">PMC5014597</ArticleId><ArticleId IdType="pubmed">27545621</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson B.S., Snead D., Lee J.J., McCaffery J.M., Shorter J., Gitler A.D. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem. 2009;284:20329&#x2013;20339. doi: 10.1074/jbc.M109.010264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.010264</ArticleId><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L., Xu M., Yang M., Yang Y., Li Y., Deng J., Ruan L., Liu J., Du S., Liu X., et al. An ALS-mutant TDP-43 neurotoxic peptide adopts an anti-parallel &#x3b2;-structure and induces TDP-43 redistribution. Hum. Mol. Genet. 2014;23:6863&#x2013;6877. doi: 10.1093/hmg/ddu409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu409</ArticleId><ArticleId IdType="pmc">PMC4245047</ArticleId><ArticleId IdType="pubmed">25113748</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Chen Y., Zhou X., Kar A., Ray P., Chen X., Rao E.J., Yang M., Ye H., Zhu L., et al. An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nat. Struct. Mol. Biol. 2011;18:822&#x2013;830. doi: 10.1038/nsmb.2053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2053</ArticleId><ArticleId IdType="pmc">PMC3357956</ArticleId><ArticleId IdType="pubmed">21666678</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada S.J., Skibinski G., Korb E., Rao E.J., Wu J.Y., Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J. Neurosci. 2010;30:639&#x2013;649. doi: 10.1523/JNEUROSCI.4988-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4988-09.2010</ArticleId><ArticleId IdType="pmc">PMC2821110</ArticleId><ArticleId IdType="pubmed">20071528</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsuzawa S., Akiyama T., Nishiyama A., Suzuki N., Kato M., Warita H., Izumi R., Osana S., Koyama S., Kato T., et al. TARDBP p.G376D mutation, found in rapid progressive familial ALS, induces mislocalization of TDP-43. eNeurologicalSci. 2018;11:20&#x2013;22. doi: 10.1016/j.ensci.2018.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2018.04.001</ArticleId><ArticleId IdType="pmc">PMC6006914</ArticleId><ArticleId IdType="pubmed">29928714</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutihac R., Alegre-Abarrategui J., Gordon D., Farrimond L., Yamasaki-Mann M., Talbot K., Wade-Martins R. TARDBP pathogenic mutations increase cytoplasmic translocation of TDP-43 and cause reduction of endoplasmic reticulum Ca2+ signaling in motor neurons. Neurobiol. Dis. 2015;75:64&#x2013;77. doi: 10.1016/j.nbd.2014.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.12.010</ArticleId><ArticleId IdType="pubmed">25526708</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin J.A., Wright G.S., Watanabe S., Grossmann J.G., Antonyuk S.V., Yamanaka K., Hasnain S.S. Disease causing mutants of TDP-43 nucleic acid binding domains are resistant to aggregation and have increased stability and half-life. Proc. Natl. Acad. Sci. USA. 2014;111:4309&#x2013;4314. doi: 10.1073/pnas.1317317111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1317317111</ArticleId><ArticleId IdType="pmc">PMC3964094</ArticleId><ArticleId IdType="pubmed">24591609</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S., Kaneko K., Yamanaka K. Accelerated disease onset with stabilized familial amyotrophic lateral sclerosis (ALS)-linked mutant TDP-43 proteins. J. Biol. Chem. 2013;288:3641&#x2013;3654. doi: 10.1074/jbc.M112.433615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.433615</ArticleId><ArticleId IdType="pmc">PMC3561582</ArticleId><ArticleId IdType="pubmed">23235148</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S., Oiwa K., Murata Y., Komine O., Sobue A., Endo F., Takahashi E., Yamanaka K. ALS-linked TDP-43(M337V) knock-in mice exhibit splicing deregulation without neurodegeneration. Mol. Brain. 2020;13:8. doi: 10.1186/s13041-020-0550-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-020-0550-4</ArticleId><ArticleId IdType="pmc">PMC6971932</ArticleId><ArticleId IdType="pubmed">31959210</ArticleId></ArticleIdList></Reference><Reference><Citation>White M.A., Kim E., Duffy A., Adalbert R., Phillips B.U., Peters O.M., Stephenson J., Yang S., Massenzio F., Lin Z., et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat. Neurosci. 2018;21:552&#x2013;563. doi: 10.1038/s41593-018-0113-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0113-5</ArticleId><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S.L., Wu L.S., Lee M., Chang C.W., Cheng W.C., Fang Y.S., Chen Y.R., Cheng P.L., Shen C.J. A robust TDP-43 knock-in mouse model of ALS. Acta Neuropathol. Commun. 2020;8:3. doi: 10.1186/s40478-020-0881-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-0881-5</ArticleId><ArticleId IdType="pmc">PMC6975031</ArticleId><ArticleId IdType="pubmed">31964415</ArticleId></ArticleIdList></Reference><Reference><Citation>Santamaria N., Alhothali M., Alfonso M.H., Breydo L., Uversky V.N. Intrinsic disorder in proteins involved in amyotrophic lateral sclerosis. Cell. Mol. Life Sci. 2017;74:1297&#x2013;1318. doi: 10.1007/s00018-016-2416-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-016-2416-6</ArticleId><ArticleId IdType="pubmed">27838743</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.J., Xu Y.F., Cook C., Gendron T.F., Roettges P., Link C.D., Lin W.L., Tong J., Castanedes-Casey M., Ash P., et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc. Natl. Acad. Sci. USA. 2009;106:7607&#x2013;7612. doi: 10.1073/pnas.0900688106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0900688106</ArticleId><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T., Hideyama T., Hachiga K., Teramoto S., Takano J., Iwata N., Saido T.C., Kwak S. A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. Nat. Commun. 2012;3:1307. doi: 10.1038/ncomms2303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2303</ArticleId><ArticleId IdType="pubmed">23250437</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebron M.L., Lonskaya I., Sharpe K., Weerasinghe P.P., Algarzae N.K., Shekoyan A.R., Moussa C.E. Parkin ubiquitinates Tar-DNA binding protein-43 (TDP-43) and promotes its cytosolic accumulation via interaction with histone deacetylase 6 (HDAC6) J. Biol. Chem. 2013;288:4103&#x2013;4115. doi: 10.1074/jbc.M112.419945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.419945</ArticleId><ArticleId IdType="pmc">PMC3567661</ArticleId><ArticleId IdType="pubmed">23258539</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter E.L., Vance C., Nishimura A.L., Lee Y.B., Chen H.J., Urwin H., Sardone V., Mitchell J.C., Rogelj B., Rubinsztein D.C., et al. Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. J. Cell Sci. 2014;127:1263&#x2013;1278. doi: 10.1242/jcs.140087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.140087</ArticleId><ArticleId IdType="pmc">PMC3953816</ArticleId><ArticleId IdType="pubmed">24424030</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T., Suzuki G., Tanaka Y., Kametani F., Hirai S., Okado H., Miyashita T., Saitoe M., Akiyama H., Masai H., et al. Phosphorylation of TAR DNA-binding protein of 43 kDa (TDP-43) by truncated casein kinase 1&#x3b4; triggers mislocalization and accumulation of TDP-43. J. Biol. Chem. 2016;291:5473&#x2013;5483. doi: 10.1074/jbc.M115.695379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.695379</ArticleId><ArticleId IdType="pmc">PMC4786690</ArticleId><ArticleId IdType="pubmed">26769969</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruijs da Silva L.A., Simonetti F., Hutten S., Riemenschneider H., Sternburg E.L., Pietrek L.M., Gebel J., D&#xf6;tsch V., Edbauer D., Hummer G., et al. Disease-linked TDP-43 hyperphosphorylation suppresses TDP-43 condensation and aggregation. EMBO J. 2022;41:E108443. doi: 10.15252/embj.2021108443.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2021108443</ArticleId><ArticleId IdType="pmc">PMC9016352</ArticleId><ArticleId IdType="pubmed">35112738</ArticleId></ArticleIdList></Reference><Reference><Citation>Eck R.J., Kraemer B.C., Liachko N.F. Regulation of TDP-43 phosphorylation in aging and disease. GeroScience. 2021;43:1605&#x2013;1614. doi: 10.1007/s11357-021-00383-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-021-00383-5</ArticleId><ArticleId IdType="pmc">PMC8492835</ArticleId><ArticleId IdType="pubmed">34032984</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji H., Nonaka T., Yamashita M., Masuda-Suzukake M., Kametani F., Akiyama H., Mann D.M., Tamaoka A., Hasegawa M. Epitope mapping of antibodies against TDP-43 and detection of protease-resistant fragments of pathological TDP-43 in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Biochem. Biophys. Res. Commun. 2012;417:116&#x2013;121. doi: 10.1016/j.bbrc.2011.11.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2011.11.066</ArticleId><ArticleId IdType="pubmed">22133678</ArticleId></ArticleIdList></Reference><Reference><Citation>Dangoumau A., Veyrat-Durebex C., Blasco H., Praline J., Corcia P., Andres C.R., Vourc&#x2019;h P. Protein SUMOylation, an emerging pathway in amyotrophic lateral sclerosis. Int. J. Neurosci. 2013;123:366&#x2013;374. doi: 10.3109/00207454.2012.761984.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00207454.2012.761984</ArticleId><ArticleId IdType="pubmed">23289752</ArticleId></ArticleIdList></Reference><Reference><Citation>Maraschi A., Gumina V., Dragotto J., Colombrita C., Mompe&#xe1;n M., Buratti E., Silani V., Feligioni M., Ratti A. SUMOylation regulates TDP-43 splicing activity and nucleocytoplasmic distribution. Mol. Neurobiol. 2021;58:5682&#x2013;5702. doi: 10.1007/s12035-021-02505-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02505-8</ArticleId><ArticleId IdType="pmc">PMC8599232</ArticleId><ArticleId IdType="pubmed">34390468</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin D.J., Cohen T.J., Grossman M., Arnold S.E., Xie S.X., Lee V.M., Trojanowski J.Q. Acetylated tau, a novel pathological signature in Alzheimer&#x2019;s disease and other tauopathies. Brain. 2012;135:807&#x2013;818. doi: 10.1093/brain/aws013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws013</ArticleId><ArticleId IdType="pmc">PMC3286338</ArticleId><ArticleId IdType="pubmed">22366796</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen T.J., Hwang A.W., Restrepo C.R., Yuan C.X., Trojanowski J.Q., Lee V.M. An acetylation switch controls TDP-43 function and aggregation propensity. Nat. Commun. 2015;6:5845. doi: 10.1038/ncomms6845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms6845</ArticleId><ArticleId IdType="pmc">PMC4407365</ArticleId><ArticleId IdType="pubmed">25556531</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Wander C.M., Yuan C.X., Bereman M.S., Cohen T.J. Acetylation-induced TDP-43 pathology is suppressed by an HSF1-dependent chaperone program. Nat. Commun. 2017;8:82. doi: 10.1038/s41467-017-00088-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00088-4</ArticleId><ArticleId IdType="pmc">PMC5517419</ArticleId><ArticleId IdType="pubmed">28724966</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H., Lu S., Gasior K., Singh D., Vazquez-Sanchez S., Tapia O., Toprani D., Beccari M.S., Yates J.R.I., Da Cruz S., et al. HSP70 chaperones RNA-free TDP-43 into anisotropic intranuclear liquid spherical shells. Science. 2021;371:6529. doi: 10.1126/science.abb4309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb4309</ArticleId><ArticleId IdType="pmc">PMC8286096</ArticleId><ArticleId IdType="pubmed">33335017</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood A., Gurfinkel Y., Polain N., Lamont W., Lyn Rea S. Molecular mechanisms underlying TDP-43 pathology in cellular and animal models of ALS and FTLD. Int. J. Mol. Sci. 2021;22:4705. doi: 10.3390/ijms22094705.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22094705</ArticleId><ArticleId IdType="pmc">PMC8125728</ArticleId><ArticleId IdType="pubmed">33946763</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala Y.M., Zago P., D&#x2019;Ambrogio A., Xu Y.F., Petrucelli L., Buratti E., Baralle F.E. Structural determinants of the cellular localization and shuttling of TDP-43. J. Cell Sci. 2008;121:3778&#x2013;3785. doi: 10.1242/jcs.038950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.038950</ArticleId><ArticleId IdType="pubmed">18957508</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E.B., Lee V.M., Trojanowski J.Q. Gains or losses: Molecular mechanisms of TDP43-mediated neurodegeneration. Nat. Rev. Neurosci. 2011;13:38&#x2013;50. doi: 10.1038/nrn3121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3121</ArticleId><ArticleId IdType="pmc">PMC3285250</ArticleId><ArticleId IdType="pubmed">22127299</ArticleId></ArticleIdList></Reference><Reference><Citation>Amlie-Wolf A., Ryvkin P., Tong R., Dragomir I., Suh E., Xu Y., Van Deerlin V.M., Gregory B.D., Kwong L.K., Trojanowski J.Q., et al. Transcriptomic changes due to cytoplasmic TDP-43 expression reveal dysregulation of histone transcripts and nuclear chromatin. PLoS ONE. 2015;10:E0141836. doi: 10.1371/journal.pone.0141836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0141836</ArticleId><ArticleId IdType="pmc">PMC4624943</ArticleId><ArticleId IdType="pubmed">26510133</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A.K., Spiller K.J., Ge G., Zheng A., Xu Y., Zhou M., Tripathy K., Kwong L.K., Trojanowski J.Q., Lee V.M. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol. 2015;130:643&#x2013;660. doi: 10.1007/s00401-015-1460-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1460-x</ArticleId><ArticleId IdType="pmc">PMC5127391</ArticleId><ArticleId IdType="pubmed">26197969</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne A.N., Zaepfel B.L., Zarnescu D.C. Failure to deliver and translate-new insights into RNA dysregulation in ALS. Front. Cell. Neurosci. 2017;11:243. doi: 10.3389/fncel.2017.00243.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00243</ArticleId><ArticleId IdType="pmc">PMC5562674</ArticleId><ArticleId IdType="pubmed">28860970</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann J.R., Gleixner A.M., Mauna J.C., Gomes E., DeChellis-Marks M.R., Needham P.G., Copley K.E., Hurtle B., Portz B., Pyles N.J., et al. RNA binding antagonizes neurotoxic phase transitions of TDP-43. Neuron. 2019;102:321&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallegger M., Chakrabarti A.M., Lee F.C.Y., Lee B.L., Amalietti A.G., Odeh H.M., Copley K.E., Rubien J.D., Portz B., Kuret K., et al. TDP-43 condensation properties specify its RNA-binding and regulatory repertoire. Cell. 2021;184:4680&#x2013;4696. doi: 10.1016/j.cell.2021.07.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.07.018</ArticleId><ArticleId IdType="pmc">PMC8445024</ArticleId><ArticleId IdType="pubmed">34380047</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold E.S., Ling S.C., Huelga S.C., Lagier-Tourenne C., Polymenidou M., Ditsworth D., Kordasiewicz H.B., McAlonis-Downes M., Platoshyn O., Parone P.A., et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc. Natl. Acad. Sci. USA. 2013;110:E736&#x2013;E745. doi: 10.1073/pnas.1222809110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1222809110</ArticleId><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim J.R., Williams L.A., Limone F., Guerra San Juan I., Davis-Dusenbery B.N., Mordes D.A., Burberry A., Steinbaugh M.J., Gamage K.K., Kirchner R., et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat. Neurosci. 2019;22:167&#x2013;179. doi: 10.1038/s41593-018-0300-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z., L&#xf3;pez-Erauskin J., Baughn M.W., Zhang O., Drenner K., Sun Y., Freyermuth F., McMahon M.A., Beccari M.S., Artates J.W., et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat. Neurosci. 2019;22:180&#x2013;190. doi: 10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A.L., Wilkins O.G., Keuss M.J., Hill S.E., Zanovello M., Lee W.C., Bampton A., Lee F.C.Y., Masino L., Qi Y.A., et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603:131&#x2013;137. doi: 10.1038/s41586-022-04436-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04436-3</ArticleId><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X.R., Prudencio M., Koike Y., Vatsavayai S.C., Kim G., Harbinski F., Briner A., Rodriguez C.M., Guo C., Akiyama T., et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature. 2022;603:124&#x2013;130. doi: 10.1038/s41586-022-04424-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P., Sivakumar P., Humphrey J., Lo K., Ricketts T., Oliveira H., Brito-Armas J.M., Kalmar B., Ule A., Yu Y., et al. Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. EMBO J. 2018;37:E98684. doi: 10.15252/embj.201798684.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201798684</ArticleId><ArticleId IdType="pmc">PMC5983119</ArticleId><ArticleId IdType="pubmed">29764981</ArticleId></ArticleIdList></Reference><Reference><Citation>Highley J.R., Kirby J., Jansweijer J.A., Webb P.S., Hewamadduma C.A., Heath P.R., Higginbottom A., Raman R., Ferraiuolo L., Cooper-Knock J., et al. Loss of nuclear TDP-43 in amyotrophic lateral sclerosis (ALS) causes altered expression of splicing machinery and widespread dysregulation of RNA splicing in motor neurones. Neuropathol. Appl. Neurobiol. 2014;40:670&#x2013;685. doi: 10.1111/nan.12148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12148</ArticleId><ArticleId IdType="pubmed">24750229</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiguro A., Kimura N., Watanabe Y., Watanabe S., Ishihama A. TDP-43 binds and transports G-quadruplex-containing mRNAs into neurites for local translation. Genes Cells. 2016;21:466&#x2013;481. doi: 10.1111/gtc.12352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/gtc.12352</ArticleId><ArticleId IdType="pubmed">26915990</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura A.L., Zupunski V., Troakes C., Kathe C., Fratta P., Howell M., Gallo J.M., Hortob&#xe1;gyi T., Shaw C.E., Rogelj B. Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain. 2010;133:1763&#x2013;1771. doi: 10.1093/brain/awq111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq111</ArticleId><ArticleId IdType="pubmed">20472655</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Kim H.J., Wang H., Monaghan J., Freyermuth F., Sung J.C., O&#x2019;Donovan K., Fare C.M., Diaz Z., Singh N., et al. Nuclear-import receptors reverse aberrant phase transitions of RNA-binding proteins with prion-like domains. Cell. 2018;173:677&#x2013;692. doi: 10.1016/j.cell.2018.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.002</ArticleId><ArticleId IdType="pmc">PMC5911940</ArticleId><ArticleId IdType="pubmed">29677512</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerner A.C., Frottin F., Hornburg D., Feng L.R., Meissner F., Patra M., Tatzelt J., Mann M., Winklhofer K.F., Hartl F.U., et al. Cytoplasmic protein aggregates interfere with nucleocytoplasmic transport of protein and RNA. Science. 2016;351:173&#x2013;176. doi: 10.1126/science.aad2033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad2033</ArticleId><ArticleId IdType="pubmed">26634439</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou C.C., Zhang Y., Umoh M.E., Vaughan S.W., Lorenzini I., Liu F., Sayegh M., Donlin-Asp P.G., Chen Y.H., Duong D.M., et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat. Neurosci. 2018;21:228&#x2013;239. doi: 10.1038/s41593-017-0047-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-017-0047-3</ArticleId><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson P., Kedersha N. Stress granules. Curr. Biol. 2009;19:R397&#x2013;R398. doi: 10.1016/j.cub.2009.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2009.03.013</ArticleId><ArticleId IdType="pubmed">19467203</ArticleId></ArticleIdList></Reference><Reference><Citation>Aulas A., Vande Velde C. Alterations in stress granule dynamics driven by TDP-43 and FUS: A link to pathological inclusions in ALS? Front. Cell. Neurosci. 2015;9:423. doi: 10.3389/fncel.2015.00423.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00423</ArticleId><ArticleId IdType="pmc">PMC4615823</ArticleId><ArticleId IdType="pubmed">26557057</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.J., Raphael A.R., LaDow E.S., McGurk L., Weber R.A., Trojanowski J.Q., Lee V.M., Finkbeiner S., Gitler A.D., Bonini N.M. Therapeutic modulation of eIF2&#x3b1; phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat. Genet. 2014;46:152&#x2013;160. doi: 10.1038/ng.2853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2853</ArticleId><ArticleId IdType="pmc">PMC3934366</ArticleId><ArticleId IdType="pubmed">24336168</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson P., Kedersha N. Stress granules: The Tao of RNA triage. Trends Biochem. Sci. 2008;33:141&#x2013;150. doi: 10.1016/j.tibs.2007.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2007.12.003</ArticleId><ArticleId IdType="pubmed">18291657</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombrita C., Zennaro E., Fallini C., Weber M., Sommacal A., Buratti E., Silani V., Ratti A. TDP-43 is recruited to stress granules in conditions of oxidative insult. J. Neurochem. 2009;111:1051&#x2013;1061. doi: 10.1111/j.1471-4159.2009.06383.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06383.x</ArticleId><ArticleId IdType="pubmed">19765185</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D., Haass C. TDP-43 and FUS: A nuclear affair. Trends Neurosci. 2011;34:339&#x2013;348. doi: 10.1016/j.tins.2011.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2011.05.002</ArticleId><ArticleId IdType="pubmed">21700347</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P., Van Hoecke A., Lambrechts D., Vanacker P., Bogaert E., van Swieten J., Carmeliet P., Van Den Bosch L., Robberecht W. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J. Cell Biol. 2008;181:37&#x2013;41. doi: 10.1083/jcb.200712039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200712039</ArticleId><ArticleId IdType="pmc">PMC2287280</ArticleId><ArticleId IdType="pubmed">18378771</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xf3;jcik C., Rowicka M., Kudlicki A., Nowis D., McConnell E., Kujawa M., DeMartino G.N. Valosin-containing protein (p97) is a regulator of endoplasmic reticulum stress and of the degradation of N-end rule and ubiquitin-fusion degradation pathway substrates in mammalian cells. Mol. Biol. Cell. 2006;17:4606&#x2013;4618. doi: 10.1091/mbc.e06-05-0432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e06-05-0432</ArticleId><ArticleId IdType="pmc">PMC1635394</ArticleId><ArticleId IdType="pubmed">16914519</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F., Lu S., Yu H., Chen C., Melamed Z., Guo L., Shorter J., Da Cruz S., Cleveland D.W. Cytoplasmic TDP-43 De-mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP-43, and cell death. Neuron. 2019;102:339&#x2013;357. doi: 10.1016/j.neuron.2019.02.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.02.038</ArticleId><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S., Hu J., Arogundade O.A., Goginashvili A., Vazquez-Sanchez S., Diedrich J.K., Gu J., Blum J., Oung S., Ye Q., et al. Heat-shock chaperone HSPB1 regulates cytoplasmic TDP-43 phase separation and liquid-to-gel transition. Nat. Cell Biol. 2022;24:1378&#x2013;1393. doi: 10.1038/s41556-022-00988-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41556-022-00988-8</ArticleId><ArticleId IdType="pubmed">36075972</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald K.K., Aulas A., Destroismaisons L., Pickles S., Beleac E., Camu W., Rouleau G.A., Vande Velde C. TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Hum. Mol. Genet. 2011;20:1400&#x2013;1410. doi: 10.1093/hmg/ddr021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr021</ArticleId><ArticleId IdType="pubmed">21257637</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewey C.M., Cenik B., Sephton C.F., Dries D.R., Mayer P.I., Good S.K., Johnson B.A., Herz J., Yu G. TDP-43 is directed to stress granules by sorbitol, a novel physiological osmotic and oxidative stressor. Mol. Cell. Biol. 2011;31:1098&#x2013;1108. doi: 10.1128/MCB.01279-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.01279-10</ArticleId><ArticleId IdType="pmc">PMC3067820</ArticleId><ArticleId IdType="pubmed">21173160</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L., Lin A.Y., Ebata A., Boon J.Y., Reid W., Xu Y.F., Kobrin K., Murphy G.J., Petrucelli L., Wolozin B. ALS-linked mutations enlarge TDP-43-enriched neuronal RNA granules in the dendritic arbor. J. Neurosci. 2014;34:4167&#x2013;4174. doi: 10.1523/JNEUROSCI.2350-13.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2350-13.2014</ArticleId><ArticleId IdType="pmc">PMC3960463</ArticleId><ArticleId IdType="pubmed">24647938</ArticleId></ArticleIdList></Reference><Reference><Citation>Besnard-Gu&#xe9;rin C. Cytoplasmic localization of amyotrophic lateral sclerosis-related TDP-43 proteins modulates stress granule formation. Eur. J. Neurosci. 2020;52:3995&#x2013;4008. doi: 10.1111/ejn.14762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.14762</ArticleId><ArticleId IdType="pubmed">32343854</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto M., Boerkoel C.F. The role of nuclear bodies in gene expression and disease. Biology. 2013;2:976&#x2013;1033. doi: 10.3390/biology2030976.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology2030976</ArticleId><ArticleId IdType="pmc">PMC3771687</ArticleId><ArticleId IdType="pubmed">24040563</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara T., Ariizumi Y., Shiga A., Kato T., Tan C.F., Sato T., Miki Y., Yokoo M., Fujino T., Koyama A., et al. Decreased number of Gemini of coiled bodies and U12 snRNA level in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2013;22:4136&#x2013;4147. doi: 10.1093/hmg/ddt262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt262</ArticleId><ArticleId IdType="pubmed">23740936</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuiji H., Iguchi Y., Furuya A., Kataoka A., Hatsuta H., Atsuta N., Tanaka F., Hashizume Y., Akatsu H., Murayama S., et al. Spliceosome integrity is defective in the motor neuron diseases ALS and SMA. EMBO Mol. Med. 2013;5:221&#x2013;234. doi: 10.1002/emmm.201202303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201202303</ArticleId><ArticleId IdType="pmc">PMC3569639</ArticleId><ArticleId IdType="pubmed">23255347</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H.R., Chen T.C., Hsiao C.L., Shi L., Chou C.Y., Huang J.R. The physical forces mediating self-association and phase-separation in the C-terminal domain of TDP-43. Biochim. Biophys. Acta Proteins Proteom. 2018;1866:214&#x2013;223. doi: 10.1016/j.bbapap.2017.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2017.10.001</ArticleId><ArticleId IdType="pubmed">28988034</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H.R., Chiang W.C., Chou P.C., Wang W.J., Huang J.R. TAR DNA-binding protein 43 (TDP-43) liquid-liquid phase separation is mediated by just a few aromatic residues. J. Biol. Chem. 2018;293:6090&#x2013;6098. doi: 10.1074/jbc.AC117.001037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.AC117.001037</ArticleId><ArticleId IdType="pmc">PMC5912450</ArticleId><ArticleId IdType="pubmed">29511089</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk L., Gomes E., Guo L., Mojsilovic-Petrovic J., Tran V., Kalb R.G., Shorter J., Bonini N.M. Poly(ADP-ribose) prevents pathological phase separation of TDP-43 by promoting liquid demixing and stress granule localization. Mol. Cell. 2018;71:703&#x2013;717. doi: 10.1016/j.molcel.2018.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2018.07.002</ArticleId><ArticleId IdType="pmc">PMC6128762</ArticleId><ArticleId IdType="pubmed">30100264</ArticleId></ArticleIdList></Reference><Reference><Citation>French R.L., Grese Z.R., Aligireddy H., Dhavale D.D., Reeb A.N., Kedia N., Kotzbauer P.T., Bieschke J., Ayala Y.M. Detection of TAR DNA-binding protein 43 (TDP-43) oligomers as initial intermediate species during aggregate formation. J. Biol. Chem. 2019;294:6696&#x2013;6709. doi: 10.1074/jbc.RA118.005889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.005889</ArticleId><ArticleId IdType="pmc">PMC6497947</ArticleId><ArticleId IdType="pubmed">30824544</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y.S., Tsai K.J., Chang Y.J., Kao P., Woods R., Kuo P.H., Wu C.C., Liao J.Y., Chou S.C., Lin V., et al. Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients. Nat. Commun. 2014;5:4824. doi: 10.1038/ncomms5824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms5824</ArticleId><ArticleId IdType="pubmed">25215604</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis S.A., Itaman S., Khalid-Janney C.M., Sherard J.A., Dowell J.A., Cairns N.J., Gitcho M.A. TDP-43 interacts with mitochondrial proteins critical for mitophagy and mitochondrial dynamics. Neurosci. Lett. 2018;678:8&#x2013;15. doi: 10.1016/j.neulet.2018.04.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2018.04.053</ArticleId><ArticleId IdType="pmc">PMC5975202</ArticleId><ArticleId IdType="pubmed">29715546</ArticleId></ArticleIdList></Reference><Reference><Citation>Kann O., Kov&#xe1;cs R. Mitochondria and neuronal activity. Am. J. Physiol. Cell Physiol. 2007;292:C641&#x2013;C657. doi: 10.1152/ajpcell.00222.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00222.2006</ArticleId><ArticleId IdType="pubmed">17092996</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Li L., Lin W.L., Dickson D.W., Petrucelli L., Zhang T., Wang X. The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. Hum. Mol. Genet. 2013;22:4706&#x2013;4719. doi: 10.1093/hmg/ddt319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt319</ArticleId><ArticleId IdType="pmc">PMC3820133</ArticleId><ArticleId IdType="pubmed">23827948</ArticleId></ArticleIdList></Reference><Reference><Citation>Magran&#xe9; J., Cortez C., Gan W.B., Manfredi G. Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. Hum. Mol. Genet. 2014;23:1413&#x2013;1424. doi: 10.1093/hmg/ddt528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt528</ArticleId><ArticleId IdType="pmc">PMC3929084</ArticleId><ArticleId IdType="pubmed">24154542</ArticleId></ArticleIdList></Reference><Reference><Citation>Altanbyek V., Cha S.J., Kang G.U., Im D.S., Lee S., Kim H.J., Kim K. Imbalance of mitochondrial dynamics in Drosophila models of amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2016;481:259&#x2013;264. doi: 10.1016/j.bbrc.2016.10.134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.10.134</ArticleId><ArticleId IdType="pubmed">27810362</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun R.J., Sommer C., Carmona-Gutierrez D., Khoury C.M., Ring J., B&#xfc;ttner S., Madeo F. Neurotoxic 43-kDa TAR DNA-binding protein (TDP-43) triggers mitochondrion-dependent programmed cell death in yeast. J. Biol. Chem. 2011;286:19958&#x2013;19972. doi: 10.1074/jbc.M110.194852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.194852</ArticleId><ArticleId IdType="pmc">PMC3103370</ArticleId><ArticleId IdType="pubmed">21471218</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Wang L., Lu J., Siedlak S.L., Fujioka H., Liang J., Jiang S., Ma X., Jiang Z., da Rocha E.L., et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat. Med. 2016;22:869&#x2013;878. doi: 10.1038/nm.4130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4130</ArticleId><ArticleId IdType="pmc">PMC4974139</ArticleId><ArticleId IdType="pubmed">27348499</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo X., Zhou J., Li Y., Wu K., Chen Z., Luo Z., Zhang X., Liang Y., Esteban M.A., Zhou Y., et al. TDP-43 aggregation induced by oxidative stress causes global mitochondrial imbalance in ALS. Nat. Struct. Mol. Biol. 2021;28:132&#x2013;142. doi: 10.1038/s41594-020-00537-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-020-00537-7</ArticleId><ArticleId IdType="pubmed">33398173</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C.H., Davidson S., Harapas C.R., Hilton J.B., Mlodzianoski M.J., Laohamonthonkul P., Louis C., Low R.R.J., Moecking J., De Nardo D., et al. TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. Cell. 2020;183:636&#x2013;649. doi: 10.1016/j.cell.2020.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.020</ArticleId><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber S.C., Mead R.J., Shaw P.J. Oxidative stress in ALS: A mechanism of neurodegeneration and a therapeutic target. Biochim. Biophys. Acta. 2006;1762:1051&#x2013;1067. doi: 10.1016/j.bbadis.2006.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.03.008</ArticleId><ArticleId IdType="pubmed">16713195</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle J.T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993;262:689&#x2013;695. doi: 10.1126/science.7901908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.7901908</ArticleId><ArticleId IdType="pubmed">7901908</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenaz G., Bovina C., D&#x2019;Aurelio M., Fato R., Formiggini G., Genova M.L., Giuliano G., Merlo Pich M., Paolucci U., Parenti Castelli G., et al. Role of mitochondria in oxidative stress and aging. Ann. N. Y. Acad. Sci. 2002;959:199&#x2013;213. doi: 10.1111/j.1749-6632.2002.tb02094.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2002.tb02094.x</ArticleId><ArticleId IdType="pubmed">11976197</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong K., Li Y., Duan W., Guo Y., Jiang H., Li W., Li C. Full-length TDP-43 and its C-terminal fragments activate mitophagy in NSC34 cell line. Neurosci. Lett. 2012;530:144&#x2013;149. doi: 10.1016/j.neulet.2012.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2012.10.003</ArticleId><ArticleId IdType="pubmed">23063673</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero E.N., Mitra J., Wang H., Rangaswamy S., Hegde P.M., Basu P., Rao K.S., Hegde M.L. Amyotrophic lateral sclerosis-associated TDP-43 mutation Q331K prevents nuclear translocation of XRCC4-DNA ligase 4 complex and is linked to genome damage-mediated neuronal apoptosis. Hum. Mol. Genet. 2019;28:2459&#x2013;2476. doi: 10.1093/hmg/ddz062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddz062</ArticleId><ArticleId IdType="pmc">PMC6659010</ArticleId><ArticleId IdType="pubmed">31067307</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter P., Ron D. The unfolded protein response: From stress pathway to homeostatic regulation. Science. 2011;334:1081&#x2013;1086. doi: 10.1126/science.1209038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1209038</ArticleId><ArticleId IdType="pubmed">22116877</ArticleId></ArticleIdList></Reference><Reference><Citation>Lautenschlaeger J., Prell T., Grosskreutz J. Endoplasmic reticulum stress and the ER mitochondrial calcium cycle in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2012;13:166&#x2013;177. doi: 10.3109/17482968.2011.641569.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.641569</ArticleId><ArticleId IdType="pubmed">22292840</ArticleId></ArticleIdList></Reference><Reference><Citation>Limanaqi F., Biagioni F., Ryskalin L., Busceti C.L., Fornai F. Molecular mechanisms linking ALS/FTD and psychiatric disorders, the potential effects of lithium. Front. Cell. Neurosci. 2019;13:450. doi: 10.3389/fncel.2019.00450.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00450</ArticleId><ArticleId IdType="pmc">PMC6797817</ArticleId><ArticleId IdType="pubmed">31680867</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica R., De Vos K.J., Paillusson S., Mueller S., Sancho R.M., Lau K.F., Vizcay-Barrena G., Lin W.L., Xu Y.F., Lewis J., et al. ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43. Nat. Commun. 2014;5:3996. doi: 10.1038/ncomms4996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms4996</ArticleId><ArticleId IdType="pmc">PMC4046113</ArticleId><ArticleId IdType="pubmed">24893131</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccaro A., Patten S.A., Aggad D., Julien C., Maios C., Kabashi E., Drapeau P., Parker J.A. Pharmacological reduction of ER stress protects against TDP-43 neuronal toxicity in vivo. Neurobiol. Dis. 2013;55:64&#x2013;75. doi: 10.1016/j.nbd.2013.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.03.015</ArticleId><ArticleId IdType="pubmed">23567652</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun R.J. Ubiquitin-dependent proteolysis in yeast cells expressing neurotoxic proteins. Front. Mol. Neurosci. 2015;8:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4357299</ArticleId><ArticleId IdType="pubmed">25814926</ArticleId></ArticleIdList></Reference><Reference><Citation>Budini M., Buratti E., Morselli E., Criollo A. Autophagy and its impact on neurodegenerative diseases: New roles for TDP-43 and C9orf72. Front. Mol. Neurosci. 2017;10:170. doi: 10.3389/fnmol.2017.00170.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00170</ArticleId><ArticleId IdType="pmc">PMC5447761</ArticleId><ArticleId IdType="pubmed">28611593</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramesh N., Pandey U.B. Autophagy dysregulation in ALS: When protein aggregates get out of hand. Front. Mol. Neurosci. 2017;10:263. doi: 10.3389/fnmol.2017.00263.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00263</ArticleId><ArticleId IdType="pmc">PMC5572252</ArticleId><ArticleId IdType="pubmed">28878620</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M., Sato T., Bamba H., Hisa Y., Tooyama I. Synergistic effect between proteasome and autophagosome in the clearance of polyubiquitinated TDP-43. J. Neurosci. Res. 2010;88:784&#x2013;797. doi: 10.1002/jnr.22243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22243</ArticleId><ArticleId IdType="pubmed">19798749</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Fan H., Ying Z., Li B., Wang H., Wang G. Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system. Neurosci. Lett. 2010;469:112&#x2013;116. doi: 10.1016/j.neulet.2009.11.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2009.11.055</ArticleId><ArticleId IdType="pubmed">19944744</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.J., Gendron T.F., Xu Y.F., Ko L.W., Yen S.H., Petrucelli L. Phosphorylation regulates proteasomal-mediated degradation and solubility of TAR DNA binding protein-43 C-terminal fragments. Mol. Neurodegener. 2010;5:33. doi: 10.1186/1750-1326-5-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-5-33</ArticleId><ArticleId IdType="pmc">PMC2941488</ArticleId><ArticleId IdType="pubmed">20804554</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantuma N.P., Bott L.C. The ubiquitin-proteasome system in neurodegenerative diseases: Precipitating factor, yet part of the solution. Front. Mol. Neurosci. 2014;7:70. doi: 10.3389/fnmol.2014.00070.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2014.00070</ArticleId><ArticleId IdType="pmc">PMC4117186</ArticleId><ArticleId IdType="pubmed">25132814</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki W., Minegishi S., Motoki K., Kume H., Hohjoh H., Araki Y.M., Tamaoka A. Disease-associated mutations of TDP-43 promote turnover of the protein through the proteasomal pathway. Mol. Neurobiol. 2014;50:1049&#x2013;1058. doi: 10.1007/s12035-014-8644-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-8644-6</ArticleId><ArticleId IdType="pubmed">24477737</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eersel J., Ke Y.D., Gladbach A., Bi M., G&#xf6;tz J., Kril J.J., Ittner L.M. Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons. PLoS ONE. 2011;6:E22850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146516</ArticleId><ArticleId IdType="pubmed">21829535</ArticleId></ArticleIdList></Reference><Reference><Citation>Tashiro Y., Urushitani M., Inoue H., Koike M., Uchiyama Y., Komatsu M., Tanaka K., Yamazaki M., Abe M., Misawa H., et al. Motor neuron-specific disruption of proteasomes, but not autophagy, replicates amyotrophic lateral sclerosis. J. Biol. Chem. 2012;287:42984&#x2013;42994. doi: 10.1074/jbc.M112.417600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.417600</ArticleId><ArticleId IdType="pmc">PMC3522293</ArticleId><ArticleId IdType="pubmed">23095749</ArticleId></ArticleIdList></Reference><Reference><Citation>Bose J.K., Huang C.C., Shen C.K. Regulation of autophagy by neuropathological protein TDP-43. J. Biol. Chem. 2011;286:44441&#x2013;44448. doi: 10.1074/jbc.M111.237115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.237115</ArticleId><ArticleId IdType="pmc">PMC3247982</ArticleId><ArticleId IdType="pubmed">22052911</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Q., Wang H., Hao Z., Fu C., Hu Q., Gao F., Ren H., Chen D., Han J., Ying Z., et al. TDP-43 loss of function increases TFEB activity and blocks autophagosome-lysosome fusion. EMBO J. 2016;35:121&#x2013;142. doi: 10.15252/embj.201591998.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201591998</ArticleId><ArticleId IdType="pmc">PMC4718457</ArticleId><ArticleId IdType="pubmed">26702100</ArticleId></ArticleIdList></Reference><Reference><Citation>King A., Maekawa S., Bodi I., Troakes C., Al-Sarraj S. Ubiquitinated, p62 immunopositive cerebellar cortical neuronal inclusions are evident across the spectrum of TDP-43 proteinopathies but are only rarely additionally immunopositive for phosphorylation-dependent TDP-43. Neuropathology. 2011;31:239&#x2013;249. doi: 10.1111/j.1440-1789.2010.01171.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1789.2010.01171.x</ArticleId><ArticleId IdType="pubmed">21118398</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland B., Kumar A., Lee S., Platt F.M., Wegiel J., Yu W.H., Nixon R.A. Autophagy induction and autophagosome clearance in neurons: Relationship to autophagic pathology in Alzheimer&#x2019;s disease. J. Neurosci. 2008;28:6926&#x2013;6937. doi: 10.1523/JNEUROSCI.0800-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0800-08.2008</ArticleId><ArticleId IdType="pmc">PMC2676733</ArticleId><ArticleId IdType="pubmed">18596167</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H.X., Chen W., Hong S.T., Boycott K.M., Gorrie G.H., Siddique N., Yang Y., Fecto F., Shi Y., Zhai H., et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011;477:211&#x2013;215. doi: 10.1038/nature10353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10353</ArticleId><ArticleId IdType="pmc">PMC3169705</ArticleId><ArticleId IdType="pubmed">21857683</ArticleId></ArticleIdList></Reference><Reference><Citation>Osaka M., Ito D., Suzuki N. Disturbance of proteasomal and autophagic protein degradation pathways by amyotrophic lateral sclerosis-linked mutations in ubiquilin 2. Biochem. Biophys. Res. Commun. 2016;472:324&#x2013;331. doi: 10.1016/j.bbrc.2016.02.107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.02.107</ArticleId><ArticleId IdType="pubmed">26944018</ArticleId></ArticleIdList></Reference><Reference><Citation>Picher-Martel V., Renaud L., Bareil C., Julien J.P. Neuronal expression of UBQLN2(P497H) exacerbates TDP-43 pathology in TDP-43(G348C) mice through interaction with ubiquitin. Mol. Neurobiol. 2019;56:4680&#x2013;4696. doi: 10.1007/s12035-018-1411-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1411-3</ArticleId><ArticleId IdType="pmc">PMC6647471</ArticleId><ArticleId IdType="pubmed">30377984</ArticleId></ArticleIdList></Reference><Reference><Citation>Maday S., Twelvetrees A.E., Moughamian A.J., Holzbaur E.L. Axonal transport: Cargo-specific mechanisms of motility and regulation. Neuron. 2014;84:292&#x2013;309. doi: 10.1016/j.neuron.2014.10.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.10.019</ArticleId><ArticleId IdType="pmc">PMC4269290</ArticleId><ArticleId IdType="pubmed">25374356</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleigh J.N., Rossor A.M., Fellows A.D., Tosolini A.P., Schiavo G. Axonal transport and neurological disease. Nat. Rev. Neurol. 2019;15:691&#x2013;703. doi: 10.1038/s41582-019-0257-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0257-2</ArticleId><ArticleId IdType="pubmed">31558780</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleigh J.N., Tosolini A.P., Gordon D., Devoy A., Fratta P., Fisher E.M.C., Talbot K., Schiavo G. Mice carrying ALS mutant TDP-43, but not mutant FUS, display in vivo defects in axonal transport of signaling endosomes. Cell Rep. 2020;30:3655&#x2013;3662. doi: 10.1016/j.celrep.2020.02.078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.02.078</ArticleId><ArticleId IdType="pmc">PMC7090381</ArticleId><ArticleId IdType="pubmed">32187538</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallini C., Bassell G.J., Rossoll W. The ALS disease protein TDP-43 is actively transported in motor neuron axons and regulates axon outgrowth. Hum. Mol. Genet. 2012;21:3703&#x2013;3718. doi: 10.1093/hmg/dds205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds205</ArticleId><ArticleId IdType="pmc">PMC3406762</ArticleId><ArticleId IdType="pubmed">22641816</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Del Tredici K., Lee V.M., Trojanowski J.Q. Spreading of pathology in neurodegenerative diseases: A focus on human studies. Nat. Rev. Neurosci. 2015;16:109&#x2013;120. doi: 10.1038/nrn3887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3887</ArticleId><ArticleId IdType="pmc">PMC4312418</ArticleId><ArticleId IdType="pubmed">25588378</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlary L., Yerbury J.J., Cashman N.R. The prion-like nature of amyotrophic lateral sclerosis. Prog. Mol. Biol. Transl. Sci. 2020;175:261&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">32958236</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal S., Kuo P.H., Chu L.Y., Golzarroshan B., Jain M., Yuan H.S. RNA recognition motifs of disease-linked RNA-binding proteins contribute to amyloid formation. Sci. Rep. 2019;9:6171. doi: 10.1038/s41598-019-42367-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-42367-8</ArticleId><ArticleId IdType="pmc">PMC6467989</ArticleId><ArticleId IdType="pubmed">30992467</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q., Boyer D.R., Sawaya M.R., Ge P., Eisenberg D.S. Cryo-EM structures of four polymorphic TDP-43 amyloid cores. Nat. Struct. Mol. Biol. 2019;26:619&#x2013;627. doi: 10.1038/s41594-019-0248-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-019-0248-4</ArticleId><ArticleId IdType="pmc">PMC7047951</ArticleId><ArticleId IdType="pubmed">31235914</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenther E.L., Cao Q., Trinh H., Lu J., Sawaya M.R., Cascio D., Boyer D.R., Rodriguez J.A., Hughes M.P., Eisenberg D.S. Atomic structures of TDP-43 LCD segments and insights into reversible or pathogenic aggregation. Nat. Struct. Mol. Biol. 2018;25:463&#x2013;471. doi: 10.1038/s41594-018-0064-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-018-0064-2</ArticleId><ArticleId IdType="pmc">PMC5990464</ArticleId><ArticleId IdType="pubmed">29786080</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T., Masuda-Suzukake M., Arai T., Hasegawa Y., Akatsu H., Obi T., Yoshida M., Murayama S., Mann D.M., Akiyama H., et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 2013;4:124&#x2013;134. doi: 10.1016/j.celrep.2013.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.06.007</ArticleId><ArticleId IdType="pubmed">23831027</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta S., Xu Y., Restrepo C.R., Kwong L.K., Zhang B., Brown H.J., Lee E.B., Trojanowski J.Q., Lee V.M. Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nat. Commun. 2018;9:4220. doi: 10.1038/s41467-018-06548-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06548-9</ArticleId><ArticleId IdType="pmc">PMC6181940</ArticleId><ArticleId IdType="pubmed">30310141</ArticleId></ArticleIdList></Reference><Reference><Citation>Smethurst P., Newcombe J., Troakes C., Simone R., Chen Y.R., Patani R., Sidle K. In vitro prion-like behaviour of TDP-43 in ALS. Neurobiol. Dis. 2016;96:236&#x2013;247. doi: 10.1016/j.nbd.2016.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.08.007</ArticleId><ArticleId IdType="pmc">PMC5113659</ArticleId><ArticleId IdType="pubmed">27590623</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeineddine R., Whiten D.R., Farrawell N.E., McAlary L., Hanspal M.A., Kumita J.R., Wilson M.R., Yerbury J.J. Flow cytometric measurement of the cellular propagation of TDP-43 aggregation. Prion. 2017;11:195&#x2013;204. doi: 10.1080/19336896.2017.1314426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19336896.2017.1314426</ArticleId><ArticleId IdType="pmc">PMC5480386</ArticleId><ArticleId IdType="pubmed">28486039</ArticleId></ArticleIdList></Reference><Reference><Citation>Feiler M.S., Strobel B., Freischmidt A., Helferich A.M., Kappel J., Brewer B.M., Li D., Thal D.R., Walther P., Ludolph A.C., et al. TDP-43 is intercellularly transmitted across axon terminals. J. Cell Biol. 2015;211:897&#x2013;911. doi: 10.1083/jcb.201504057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201504057</ArticleId><ArticleId IdType="pmc">PMC4657165</ArticleId><ArticleId IdType="pubmed">26598621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra P.S., Boutej H., Soucy G., Bareil C., Kumar S., Picher-Martel V., Dupr&#xe9; N., Kriz J., Julien J.P. Transmission of ALS pathogenesis by the cerebrospinal fluid. Acta Neuropathol. Commun. 2020;8:65. doi: 10.1186/s40478-020-00943-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-00943-4</ArticleId><ArticleId IdType="pmc">PMC7206749</ArticleId><ArticleId IdType="pubmed">32381112</ArticleId></ArticleIdList></Reference><Reference><Citation>Burda J.E., Sofroniew M.V. Reactive gliosis and the multicellular response to CNS damage and disease. Neuron. 2014;81:229&#x2013;248. doi: 10.1016/j.neuron.2013.12.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.12.034</ArticleId><ArticleId IdType="pmc">PMC3984950</ArticleId><ArticleId IdType="pubmed">24462092</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke L.E., Barres B.A. Emerging roles of astrocytes in neural circuit development. Nat. Rev. Neurosci. 2013;14:311&#x2013;321. doi: 10.1038/nrn3484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3484</ArticleId><ArticleId IdType="pmc">PMC4431630</ArticleId><ArticleId IdType="pubmed">23595014</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K., Komine O. The multi-dimensional roles of astrocytes in ALS. Neurosci. Res. 2018;126:31&#x2013;38. doi: 10.1016/j.neures.2017.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2017.09.011</ArticleId><ArticleId IdType="pubmed">29054467</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy D., Kato T., Kushner P.D. Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis. J. Neurosci. Res. 1994;38:336&#x2013;347. doi: 10.1002/jnr.490380312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.490380312</ArticleId><ArticleId IdType="pubmed">7523689</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallings N.R., Puttaparthi K., Luther C.M., Burns D.K., Elliott J.L. Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol. Dis. 2010;40:404&#x2013;414. doi: 10.1016/j.nbd.2010.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2010.06.017</ArticleId><ArticleId IdType="pubmed">20621187</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y.F., Zhang Y.J., Lin W.L., Cao X., Stetler C., Dickson D.W., Lewis J., Petrucelli L. Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. Mol. Neurodegener. 2011;6:73. doi: 10.1186/1750-1326-6-73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-6-73</ArticleId><ArticleId IdType="pmc">PMC3216869</ArticleId><ArticleId IdType="pubmed">22029574</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong J., Huang C., Bi F., Wu Q., Huang B., Liu X., Li F., Zhou H., Xia X.G. Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats. EMBO J. 2013;32:1917&#x2013;1926. doi: 10.1038/emboj.2013.122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2013.122</ArticleId><ArticleId IdType="pmc">PMC3981181</ArticleId><ArticleId IdType="pubmed">23714777</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y.H., Parsadanian A.S., Andreeva A., Snider W.D., Elliott J.L. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J. Neurosci. 2000;20:660&#x2013;665. doi: 10.1523/JNEUROSCI.20-02-00660.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-02-00660.2000</ArticleId><ArticleId IdType="pmc">PMC6772423</ArticleId><ArticleId IdType="pubmed">10632595</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I.R., Rademakers R., Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010;9:995&#x2013;1007. doi: 10.1016/S1474-4422(10)70195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70195-2</ArticleId><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>Prater K.E., Latimer C.S., Jayadev S. Glial TDP-43 and TDP-43 induced glial pathology, focus on neurodegenerative proteinopathy syndromes. Glia. 2022;70:239&#x2013;255. doi: 10.1002/glia.24096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.24096</ArticleId><ArticleId IdType="pmc">PMC8722378</ArticleId><ArticleId IdType="pubmed">34558120</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Ho W.Y., Lim K., Feng J., Tucker-Kellogg G., Nave K.A., Ling S.C. Cell-autonomous requirement of TDP-43, an ALS/FTD signature protein, for oligodendrocyte survival and myelination. Proc. Natl. Acad. Sci. USA. 2018;115:E10941&#x2013;E10950. doi: 10.1073/pnas.1809821115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1809821115</ArticleId><ArticleId IdType="pmc">PMC6243235</ArticleId><ArticleId IdType="pubmed">30373824</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida T., Tamaki Y., Ayaki T., Shodai A., Kaji S., Morimura T., Banno Y., Nishitsuji K., Sakashita N., Maki T., et al. CUL2-mediated clearance of misfolded TDP-43 is paradoxically affected by VHL in oligodendrocytes in ALS. Sci. Rep. 2016;6:19118. doi: 10.1038/srep19118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep19118</ArticleId><ArticleId IdType="pmc">PMC4707540</ArticleId><ArticleId IdType="pubmed">26751167</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Kwong L.K., Lee E.B., Kremmer E., Flatley A., Xu Y., Forman M.S., Troost D., Kretzschmar H.A., Trojanowski J.Q., et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117:137&#x2013;149. doi: 10.1007/s00401-008-0477-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0477-9</ArticleId><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz L.M., Kwong L.K., Xu Y., Truax A.C., Uryu K., Neumann M., Clark C.M., Elman L.B., Miller B.L., Grossman M., et al. Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am. J. Pathol. 2008;173:182&#x2013;194. doi: 10.2353/ajpath.2008.080003.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2008.080003</ArticleId><ArticleId IdType="pmc">PMC2438296</ArticleId><ArticleId IdType="pubmed">18535185</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory J.M., McDade K., Bak T.H., Pal S., Chandran S., Smith C., Abrahams S. Executive, language and fluency dysfunction are markers of localised TDP-43 cerebral pathology in non-demented ALS. J. Neurol. Neurosurg. Psychiatry. 2020;91:149&#x2013;157. doi: 10.1136/jnnp-2019-320807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320807</ArticleId><ArticleId IdType="pmc">PMC6996101</ArticleId><ArticleId IdType="pubmed">31515300</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudlo J., K&#xf6;nig J., Schuster C., Kasper E., B&#xfc;ttner A., Teipel S., Neumann M. TDP-43 pathology and cognition in ALS: A prospective clinicopathologic correlation study. Neurology. 2016;87:1019&#x2013;1023. doi: 10.1212/WNL.0000000000003062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003062</ArticleId><ArticleId IdType="pubmed">27488596</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannini L.A.A., Xie S.X., McMillan C.T., Liang M., Williams A., Jester C., Rascovsky K., Wolk D.A., Ash S., Lee E.B., et al. Divergent patterns of TDP-43 and tau pathologies in primary progressive aphasia. Ann. Neurol. 2019;85:630&#x2013;643. doi: 10.1002/ana.25465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25465</ArticleId><ArticleId IdType="pmc">PMC6538935</ArticleId><ArticleId IdType="pubmed">30851133</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I.R., Neumann M., Baborie A., Sampathu D.M., Du Plessis D., Jaros E., Perry R.H., Trojanowski J.Q., Mann D.M., Lee V.M. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122:111&#x2013;113. doi: 10.1007/s00401-011-0845-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0845-8</ArticleId><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Mossevelde S., Engelborghs S., van der Zee J., Van Broeckhoven C. Genotype-phenotype links in frontotemporal lobar degeneration. Nat. Rev. Neurol. 2018;14:363&#x2013;378. doi: 10.1038/s41582-018-0009-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0009-8</ArticleId><ArticleId IdType="pubmed">29777184</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellami L., Saracino D., Le Ber I. Genetic forms of frontotemporal lobar degeneration: Current diagnostic approach and new directions in therapeutic strategies. Rev. Neurol. 2020;176:571&#x2013;581. doi: 10.1016/j.neurol.2020.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2020.02.008</ArticleId><ArticleId IdType="pubmed">32312500</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve B.F., Boylan K.B., Graff-Radford N.R., DeJesus-Hernandez M., Knopman D.S., Pedraza O., Vemuri P., Jones D., Lowe V., Murray M.E., et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain. 2012;135:765&#x2013;783. doi: 10.1093/brain/aws004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws004</ArticleId><ArticleId IdType="pmc">PMC3286335</ArticleId><ArticleId IdType="pubmed">22366793</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed R.M., Caga J., Devenney E., Hsieh S., Bartley L., Highton-Williamson E., Ramsey E., Zoing M., Halliday G.M., Piguet O., et al. Cognition and eating behavior in amyotrophic lateral sclerosis: Effect on survival. J. Neurol. 2016;263:1593&#x2013;1603. doi: 10.1007/s00415-016-8168-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-016-8168-2</ArticleId><ArticleId IdType="pubmed">27260291</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed R.M., Newcombe R.E., Piper A.J., Lewis S.J., Yee B.J., Kiernan M.C., Grunstein R.R. Sleep disorders and respiratory function in amyotrophic lateral sclerosis. Sleep Med. Rev. 2016;26:33&#x2013;42. doi: 10.1016/j.smrv.2015.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smrv.2015.05.007</ArticleId><ArticleId IdType="pubmed">26166297</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Pradat P.F., Ludolph A.C., Loeffler J.P. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75&#x2013;82. doi: 10.1016/S1474-4422(10)70224-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70224-6</ArticleId><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R., Kurihara M., Ogawa N., Kitamura A., Yamakawa I., Bamba S., Sanada M., Sasaki M., Urushitani M. Prognostic prediction by hypermetabolism varies depending on the nutritional status in early amyotrophic lateral sclerosis. Sci. Rep. 2021;11:17943. doi: 10.1038/s41598-021-97196-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-97196-5</ArticleId><ArticleId IdType="pmc">PMC8429558</ArticleId><ArticleId IdType="pubmed">34504168</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabery S., Ahmed R.M., Caga J., Kiernan M.C., Halliday G.M., Peters&#xe9;n &#xc5;. Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 2021;47:979&#x2013;989. doi: 10.1111/nan.12709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12709</ArticleId><ArticleId IdType="pubmed">33755993</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki K., Araki A., Honda D., Izumoto T., Hashizume A., Hijikata Y., Yamada S., Iguchi Y., Hara A., Ikumi K., et al. TDP-43 regulates early-phase insulin secretion via CaV1.2-mediated exocytosis in islets. J. Clin. Investig. 2019;129:3578&#x2013;3593. doi: 10.1172/JCI124481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI124481</ArticleId><ArticleId IdType="pmc">PMC6715357</ArticleId><ArticleId IdType="pubmed">31355778</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurashige T., Morino H., Murao T., Izumi Y., Sugiura T., Kuraoka K., Kawakami H., Torii T., Maruyama H. TDP-43 accumulation within intramuscular nerve bundles of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2022;79:693&#x2013;701. doi: 10.1001/jamaneurol.2022.1113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2022.1113</ArticleId><ArticleId IdType="pmc">PMC9127711</ArticleId><ArticleId IdType="pubmed">35604654</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S., Tian D., Chong P.S., Cudkowicz M.E., Hedley-Whyte E.T., Cros D. Facial onset sensory and motor neuronopathy (FOSMN syndrome): A novel syndrome in neurology. Brain. 2006;129:3384&#x2013;3390. doi: 10.1093/brain/awl258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl258</ArticleId><ArticleId IdType="pubmed">17012296</ArticleId></ArticleIdList></Reference><Reference><Citation>De Boer E.M.J., Barritt A.W., Elamin M., Anderson S.J., Broad R., Nisbet A., Goedee H.S., Vazquez Costa J.F., Prudlo J., Vedeler C.A., et al. Facial onset sensory and motor neuronopathy: New cases, cognitive changes, and pathophysiology. Neurol. Clin. Pract. 2021;11:147&#x2013;157. doi: 10.1212/CPJ.0000000000000834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0000000000000834</ArticleId><ArticleId IdType="pmc">PMC8032419</ArticleId><ArticleId IdType="pubmed">33842068</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossor A.M., Jaunmuktane Z., Rossor M.N., Hoti G., Reilly M.M. TDP43 pathology in the brain, spinal cord, and dorsal root ganglia of a patient with FOSMN. Neurology. 2019;92:E951&#x2013;E956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6404468</ArticleId><ArticleId IdType="pubmed">30700593</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonoda K., Sasaki K., Tateishi T., Yamasaki R., Hayashi S., Sakae N., Ohyagi Y., Iwaki T., Kira J. TAR DNA-binding protein 43 pathology in a case clinically diagnosed with facial-onset sensory and motor neuronopathy syndrome: An autopsied case report and a review of the literature. J. Neurol. Sci. 2013;332:148&#x2013;153. doi: 10.1016/j.jns.2013.06.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2013.06.027</ArticleId><ArticleId IdType="pubmed">23849263</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziso B., Williams T.L., Walters R.J., Jaiser S.R., Attems J., Wieshmann U.C., Larner A.J., Jacob A. Facial onset sensory and motor neuronopathy: Further evidence for a TDP-43 proteinopathy. Case Rep. Neurol. 2015;7:95&#x2013;100. doi: 10.1159/000381944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000381944</ArticleId><ArticleId IdType="pmc">PMC4448067</ArticleId><ArticleId IdType="pubmed">26327906</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi S., Iseki E., Yamamoto R., Minegishi M., Hino H., Fujisawa K., Togo T., Katsuse O., Uchikado H., Furukawa Y., et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer&#x2019;s disease and dementia with Lewy bodies. Brain Res. 2007;1184:284&#x2013;294. doi: 10.1016/j.brainres.2007.09.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.09.048</ArticleId><ArticleId IdType="pubmed">17963732</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs K.A., Murray M.E., Whitwell J.L., Parisi J.E., Petrucelli L., Jack C.R., Petersen R.C., Dickson D.W. Staging TDP-43 pathology in Alzheimer&#x2019;s disease. Acta Neuropathol. 2014;127:441&#x2013;450. doi: 10.1007/s00401-013-1211-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1211-9</ArticleId><ArticleId IdType="pmc">PMC3944799</ArticleId><ArticleId IdType="pubmed">24240737</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanson J.B., Echaniz-Laguna A., Vogel T., Mohr M., Benoilid A., Kaltenbach G., Kiesmann M. TDP43-positive intraneuronal inclusions in a patient with motor neuron disease and Parkinson&#x2019;s disease. Neurodegener. Dis. 2010;7:260&#x2013;264. doi: 10.1159/000273591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000273591</ArticleId><ArticleId IdType="pubmed">20197650</ArticleId></ArticleIdList></Reference><Reference><Citation>Markopoulou K., Dickson D.W., McComb R.D., Wszolek Z.K., Katechalidou L., Avery L., Stansbury M.S., Chase B.A. Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson&#x2019;s disease. Variability in familial Parkinson&#x2019;s disease. Acta Neuropathol. 2008;116:25&#x2013;35. doi: 10.1007/s00401-008-0372-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0372-4</ArticleId><ArticleId IdType="pmc">PMC2728685</ArticleId><ArticleId IdType="pubmed">18389263</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab C., Arai T., Hasegawa M., Yu S., McGeer P.L. Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J. Neuropathol. Exp. Neurol. 2008;67:1159&#x2013;1165. doi: 10.1097/NEN.0b013e31818e8951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31818e8951</ArticleId><ArticleId IdType="pubmed">19018245</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu K., Nakashima-Yasuda H., Forman M.S., Kwong L.K., Clark C.M., Grossman M., Miller B.L., Kretzschmar H.A., Lee V.M., Trojanowski J.Q., et al. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J. Neuropathol. Exp. Neurol. 2008;67:555&#x2013;564. doi: 10.1097/NEN.0b013e31817713b5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31817713b5</ArticleId><ArticleId IdType="pmc">PMC3659339</ArticleId><ArticleId IdType="pubmed">18520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga S., Sanchez-Contreras M., Josephs K.A., Uitti R.J., Graff-Radford N., Van Gerpen J.A., Cheshire W.P., Wszolek Z.K., Rademakers R., Dickson D.W. Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. Mov. Disord. 2017;32:246&#x2013;255. doi: 10.1002/mds.26809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26809</ArticleId><ArticleId IdType="pmc">PMC5933946</ArticleId><ArticleId IdType="pubmed">28009087</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokota O., Davidson Y., Bigio E.H., Ishizu H., Terada S., Arai T., Hasegawa M., Akiyama H., Sikkink S., Pickering-Brown S., et al. Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta Neuropathol. 2010;120:55&#x2013;66. doi: 10.1007/s00401-010-0702-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0702-1</ArticleId><ArticleId IdType="pmc">PMC2901929</ArticleId><ArticleId IdType="pubmed">20512649</ArticleId></ArticleIdList></Reference><Reference><Citation>Riku Y., Iwasaki Y., Ishigaki S., Akagi A., Hasegawa M., Nishioka K., Li Y., Riku M., Ikeuchi T., Fujioka Y., et al. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration. Brain. 2022;145:2769&#x2013;2784. doi: 10.1093/brain/awac091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac091</ArticleId><ArticleId IdType="pubmed">35274674</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F., Winton M.J., Kwong L.K., Xu Y., Xie S.X., Igaz L.M., Garruto R.M., Perl D.P., Galasko D., Lee V.M., et al. Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol. 2008;115:133&#x2013;145. doi: 10.1007/s00401-007-0257-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0257-y</ArticleId><ArticleId IdType="pubmed">17713769</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M., Arai T., Akiyama H., Nonaka T., Mori H., Hashimoto T., Yamazaki M., Oyanagi K. TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain. 2007;130:1386&#x2013;1394. doi: 10.1093/brain/awm065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm065</ArticleId><ArticleId IdType="pubmed">17439983</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishima T., Fujioka S., Tomiyama H., Yabe I., Kurisaki R., Fujii N., Neshige R., Ross O.A., Farrer M.J., Dickson D.W., et al. Establishing diagnostic criteria for Perry syndrome. J. Neurol. Neurosurg. Psychiatry. 2018;89:482&#x2013;487. doi: 10.1136/jnnp-2017-316864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316864</ArticleId><ArticleId IdType="pmc">PMC5909757</ArticleId><ArticleId IdType="pubmed">29089398</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshimaru M., Kinoshita-Kawada M., Kubota K., Watanabe T., Tanaka Y., Hirano S., Ishidate F., Hiramoto M., Ishikawa M., Uehara Y., et al. DCTN1 binds to TDP-43 and regulates TDP-43 aggregation. Int. J. Mol. Sci. 2021;22:3985. doi: 10.3390/ijms22083985.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22083985</ArticleId><ArticleId IdType="pmc">PMC8070438</ArticleId><ArticleId IdType="pubmed">33924373</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>